NCT05983159 2026-02-19
TARGET-VM
Murdoch Childrens Research Institute
Phase 2 Recruiting
Clinical Trials
13 trialsNCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT03138070 2026-01-28
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Completed
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT06083038 2025-12-31
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
HealthPartners Institute
Active not recruiting
NCT05090358 2025-10-27
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05143229 2025-10-06
ASSET
University of Kansas Medical Center
Phase 1 Active not recruiting
NCT04216472 2025-09-30
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05063786 2025-09-08
ALPHABET
Spanish Breast Cancer Research Group
Phase 3 Active not recruiting
NCT05625087 2025-08-20
SAFIR 03
UNICANCER
Phase 2 Active not recruiting
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed